Medicare Expanded Coverage for Heart Valve Procedure
Adults with asymptomatic severe aortic stenosis now have broader access to minimally invasive valve replacement.
Updated on Sept. 21, 2026 in Heart Disease
Live Poll
Should Medicare expand coverage for medical procedures before patients show clear symptoms?
The Centers for Medicare & Medicaid Services has finalized a policy expansion for transcatheter aortic valve replacement (TAVR). This update now covers patients with severe aortic stenosis before they begin to show symptoms of the condition.
Why it matters
This change removes clinical study requirements for symptomatic patients and broadens care access for millions of older adults. It reflects a shift toward providing timely intervention for those living with significant heart valve disease.
The federal policy revision impacts a population of 2.5 million Americans over age 75 diagnosed with aortic stenosis. While clinical data support the shift, the long-term health outcomes for asymptomatic patients remain under investigation.
The players
Centers for Medicare & Medicaid Services
The federal agency responsible for administering Medicare and establishing national coverage policies for medical procedures.
Edwards Lifesciences
A medical technology company based in Irvine, California, that specializes in cardiovascular disease treatments and heart valve replacement devices.
The details
TAVR is a procedure that replaces a diseased heart valve using a minimally invasive approach, avoiding the need for open-heart surgery. By removing the requirement for patients to be enrolled in a clinical study to receive coverage, the policy provides heart teams greater flexibility in treatment timing and clinical decision-making.
Timeline
July 2025: Edwards Lifesciences petitioned CMS for coverage reconsideration.
Sept. 10, 2026: CMS finalized the decision to expand TAVR coverage.
Nov. 3, 2026: Edwards Lifesciences is scheduled to present results from the Progress trial.
December 2026: Edwards Lifesciences will provide updated long-term financial guidance.
Health Landscape
This decision represents a formal update to existing Medicare coverage guidelines for TAVR. It marks a shift from requiring clinical trial participation to allowing expanded access for asymptomatic patients.
If you are an older adult diagnosed with aortic stenosis, discuss with your cardiologist whether this policy change affects your treatment options. Patients should consult their care team to determine if early intervention is appropriate based on their specific health profile.
The takeaway
The new CMS policy increases options for treating severe aortic stenosis by covering TAVR before symptoms emerge. If you or a loved one have a history of heart valve issues, ask your doctor about current screening guidelines and whether you are a candidate for early evaluation.
Further reading
Learn more about the latest diagnostic and treatment trends in Heart Disease.
Source note: This article includes information reported by Orange County Business Journal.
Live Poll
Should Medicare expand coverage for medical procedures before patients show clear symptoms?
